News blog

NextGen Group

  • BY: Andrew Hore |
  • POSTED: 05/12/2008 |

Biomarker testing services provider NextGen Group is selling its non-core business.

The gene to protein automation and software business is being bought by its management. They will exclusively licence the technology but NextGen is able to recognise revenues of £300,000 from two existing orders in 2008 and further £900,000 in 2009.

The company buying the business is called eXeTek and it will receive £200,000 for taking on the liabilities of the business and giving up the revenues from the two contracts.

NextGen will effectively make a net profit of £600,000 on the deal as well as taking a 24% stake in eXeTek. NextGen will also receive royalties of 5% on sales for the next three years.

At 0.125p a share, NextGen is valued at £3.18m.

© 2019 Aim Micro. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.

Browse by issue
All issues
Popular tags
All tags

betbrokers, financial, gold, health, leisure, media, mobile, resources, services, technology

AIM Micro feeds

Keep up to date with articles published at Subscribe to AIM Micro RSS Feeds